Is It Time To Reassess ImmunityBio (IBRX) After Its Recent Share Price Surge

Simply Wall St.03-10

If you are wondering whether ImmunityBio's current share price really reflects its potential, you are not alone. This article focuses on what the numbers suggest about value rather than short term ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2618939703?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-03-10 17:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2618939703","market":"nz","top_or_hot":-1,"title":"Is It Time To Reassess ImmunityBio (IBRX) After Its Recent Share Price Surge","media":"Simply Wall St.","content":"<div>\n<p>If you are wondering whether ImmunityBio's current share price really reflects its potential, you are not alone. This article focuses on what the numbers suggest about value rather than short term ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ibrx/immunitybio/news/is-it-time-to-reassess-immunitybio-ibrx-after-its-recent-sha\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is It Time To Reassess ImmunityBio (IBRX) After Its Recent Share Price Surge</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs It Time To Reassess ImmunityBio (IBRX) After Its Recent Share Price Surge\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-10 17:16 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ibrx/immunitybio/news/is-it-time-to-reassess-immunitybio-ibrx-after-its-recent-sha><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>If you are wondering whether ImmunityBio's current share price really reflects its potential, you are not alone. This article focuses on what the numbers suggest about value rather than short term ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ibrx/immunitybio/news/is-it-time-to-reassess-immunitybio-ibrx-after-its-recent-sha\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ibrx/immunitybio/news/is-it-time-to-reassess-immunitybio-ibrx-after-its-recent-sha","article_id":"2618939703","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ibrx/immunitybio/news/is-it-time-to-reassess-immunitybio-ibrx-after-its-recent-sha","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2618939703","pubTimestamp":1773134182,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"If you are wondering whether ImmunityBio's current share price really reflects its potential, you are not alone. This article focuses on what the numbers suggest about value rather than short term excitement.\nThe stock closed at US$8.45 most recently, with returns of 39.7% over 30 days, 318.3% year to date and 190.4% over 1 year, although the last 7 days saw a 19.1% decline and the 5 year return sits at a 72.6% loss.\nThese swings have come alongside ongoing interest in ImmunityBio's pipeline...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","IBRX":"ImmunityBio, Inc.","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc"},"translate_title":"ImmunityBio(IBRX)近期股价飙升后，是时候重新评估其股价了吗？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IBRX":1.5,"DCF":1},"content_text":"If you are wondering whether ImmunityBio's current share price really reflects its potential, you are not alone. This article focuses on what the numbers suggest about value rather than short term excitement. The stock closed at US$8.45 most recently, with returns of 39.7% over 30 days, 318.3% year to date and 190.4% over 1 year, although the last 7 days saw a 19.1% decline and the 5 year return sits at a 72.6% loss. These swings have come alongside ongoing interest in ImmunityBio's pipeline and regulatory progress, with recent headlines keeping attention on how its clinical developments could affect long term prospects. That backdrop helps explain why sentiment around the stock has been shifting so quickly, even without focusing on quarterly earnings updates. Simply Wall St currently gives ImmunityBio a valuation score of 2 out of 6, which means it screens as undervalued on 2 of 6 checks. Next we will walk through what traditional valuation methods say, before finishing with a broader way to think about value that goes beyond any single model.  ImmunityBio scores just 2/6 on our valuation checks. See what other red flags we found in the full valuation breakdown. AdvertisementApproach 1: ImmunityBio Discounted Cash Flow (DCF) Analysis A Discounted Cash Flow model estimates what a company might be worth by projecting its future cash flows, then discounting those back into today’s dollars. It is essentially asking what the stream of expected future cash flows is worth right now. For ImmunityBio, the model used is a 2 Stage Free Cash Flow to Equity approach. The latest twelve month free cash flow is a loss of about $341.7 million. Analyst and extrapolated forecasts then move from negative free cash flow in 2026 and 2027 into positive territory, reaching projected free cash flow of about $1.44 billion in 2030, all in US$ terms. When these projected cash flows are discounted back to today, Simply Wall St’s DCF model arrives at an estimated intrinsic value of about $49.64 per share. Compared with the recent share price of $8.45, this implies the stock screens as around 83.0% undervalued on this model alone. Result: UNDERVALUED Our Discounted Cash Flow (DCF) analysis suggests ImmunityBio is undervalued by 83.0%. Track this in your watchlist or portfolio, or discover 46 more high quality undervalued stocks. IBRX Discounted Cash Flow as at Mar 2026 Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for ImmunityBio. Approach 2: ImmunityBio Price vs Book (P/B) For profitable companies with meaningful assets on the balance sheet, price to book, or P/B, is a useful cross check because it compares what the market is paying to the accounting value of net assets per share. Investors usually expect a higher P/B when they see stronger growth potential and lower perceived risk, and a lower P/B when growth is more uncertain or risk is higher. ImmunityBio currently trades on a P/B of 17.36x. That is well above the Biotechs industry average P/B of about 2.72x and also above the peer group average of roughly 15.10x. On simple comparisons like these, the shares look expensive relative to many other biotech names. Simply Wall St’s Fair Ratio is designed to refine this picture. It is a proprietary P/B estimate that reflects factors such as earnings growth expectations, profit margins, industry, market cap and company specific risks. Because it adjusts for these elements, it can be more informative than a basic peer or industry average. In this case, the Fair Ratio is not available, so it is not possible to say whether the current 17.36x P/B points to under or overvaluation using this framework. Result: ABOUT RIGHT NasdaqGS:IBRX P/B Ratio as at Mar 2026 P/B ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies. Upgrade Your Decision Making: Choose your ImmunityBio Narrative Earlier we mentioned that there is an even better way to understand valuation. On Simply Wall St’s Community page you can use Narratives, where you set a clear story for ImmunityBio, link that story to your own forecast for revenue, earnings and margins, and then compare your fair value to the current price. The platform automatically updates your view as new news or earnings arrive and shows, for example, how one investor might see ImmunityBio as worth US$23.00 while another sees only US$7.00. All of this is available within an easy tool used by millions of investors to help decide whether a stock looks closer to a buy, hold or sell for them. Do you think there's more to the story for ImmunityBio? Head over to our Community to see what others are saying! NasdaqGS:IBRX 1-Year Stock Price Chart  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2618939703","isCrawlerRequest":true}